Objective-Strategies to inhibit or reverse cholesterol accumulation in macrophages have been shown to be atheroprotective. Notably, the administration of LXR agonists upregulates key players in the reverse cholesterol transport pathway, including the ABCA1 and ABCG1 transporters. However, the effects of natural LXR activators, oxysterols, on lipid-laden macrophages remains elusive. Methods and Results-We assessed the ability of 2 oxysterols, 22(R)-hydroxycholesterol (22-OH) and 24(S), 25-epoxycholesterol (epoxycholesterol), to promote cholesterol efflux to apoA-I from LDL-and modified LDL-labeled and loaded macrophages and thus rescue the phenotype associated with the accumulation of cellular cholesterol in these cells. In macrophages labeled with LDL-derived cholesterol, epoxycholesterol treatment enhances ABCA1-mediated cholesterol efflux. In contrast, in AcLDL-loaded macrophages, epoxycholesterol treatment decreases cholesterol efflux to apoA-I, despite a dramatic increase in the expression of ABCA1 in response to epoxycholesterol treatment. We show that the decreased efflux is attributable to impaired cholesterol mobilization from lipid droplets, resulting from decreased cholesteryl ester hydrolase activity. 
W hereas low density lipoprotein (LDL) endocytosis is a regulated process, the uptake of modified LDL via macrophage scavenger receptors 1 or via macropinocytosis 2 lacks feedback inhibition by intracellular cholesterol accumulation. The internalization of modified LDL, such as oxidized LDL (OxLDL), acetylated LDL (AcLDL), or aggregated LDL (AgLDL), leads to the formation of foam cells, 3, 4 which are a major component of atherosclerotic lesions.
The liver X receptors (LXRs) ␣ and ␤, members of the nuclear receptor family of transcription factors, are key regulators of whole body lipid homeostasis. LXR-␤ is expressed ubiquitously whereas LXR-␣ is predominantly expressed in tissues important in lipid metabolism including liver, adipose tissue, and macrophages. 5, 6 The naturally occurring oxysterols 22(R)-hydroxycholesterol (22-HC) and 24(S),25-epoxycholesterol (epoxycholesterol) are endogenous LXR ligands and have been shown to be potent physiological activators of both LXRs. 7, 8 LXRs function by forming an obligate heterodimer with the retinoid X receptor (RXR), and this complex drives LXR-dependent transactivation of multiple genes involved in cellular cholesterol homeostasis, including ABCA1, ABCG1, and apoE in the lipid efflux pathway, which normally prevent cholesterol accumulation as intracellular lipid droplets. 9 Given that ABCA1-mediated cholesterol efflux to lipidpoor apolipoprotein A-I (apoA-I) is the preferred efflux pathway of the macrophage foam cell, 10 we sought to promote this pathway in cholesterol-loaded cells using 22-HC and epoxycholesterol. Oxysterols have been shown to be beneficial for enhancing cholesterol efflux 6, [11] [12] [13] and preventing foam cell formation, 14 but it is not established whether they are similarly effective when macrophages become cholesterol-loaded. Large quantities of excess lipoproteinderived cholesterol are esterified by the ER-resident protein, acyl-coenzyme A (CoA):cholesterol acyl transferase (ACAT) and stored as cholesteryl esters (CE) in cytoplasmic lipid droplets. 15 Unesterified cholesterol can be released from the lipid droplets via CE hydrolysis, and subsequently effluxed to a cholesterol acceptor or reesterified by ACAT. 16 Unexpectedly, we found that whereas 22-HC enhanced cholesterol efflux from AcLDL-loaded macrophages, epoxycholesterol promoted cholesterol efflux only in unloaded or LDL-labeled macrophages. Despite inducing a dramatic increase in ABCA1 protein, epoxycholesterol impaired CE hydrolysis in lipid droplets of macrophage foam cells and reduced efflux to apoA-I, resulting in a net increase of CE and exacerbation of the foam cell phenotype. ) . Human recombinant apoA-I was produced as previously described. 17 The Sandoz 58 to 035 ACAT inhibitor was a kind gift from Novartis (Basel, Switzerland).
Materials and Methods

Materials
Cell Culture
Bone marrow-derived macrophages (BMDM): hematopoietic stem cells were flushed from the femurs of C57Bl6 mice (Jackson Laboratories) and differentiated into mature macrophages by incubation in DMEM media supplemented with 10% FBS, 1% P/S, and 15% L929-conditioned medium for 7 days. Monocyte-derived macrophages (MDM): mononuclear cells were isolated from the blood of normolipemic volunteers, and differentiated to macrophages, as previously described. 18 THP-1 human monocytes (ATCC) were cultured in complete growth medium (RPMI 1640 supplemented with 10% FBS, 0.05 mmol/L 2-mercaptoethanol, and 1% P/S), and were differentiated by treatment with PMA (100 nmol/L) for 7 days.
Lipoprotein Preparation
Plasma was collected from normolipemic volunteers. LDL and HDL were isolated by sequential density ultracentrifugation, as previously described. 19, 20 Modification of LDL: LDL was acetylated by repetitive additions of acetic anhydride, 21 aggregated by vortexing, 22 or oxidized by incubation with 5 mol/L CuSO 4 at room temperature for 24 hours, adapted from Kunjathoor et al. 23 
Efflux of Exogenously Delivered Cholesterol
Differentiated macrophages were incubated for 24 hours in medium (1% FBS, 1% P/S DMEM) containing LDL or AcLDL (50 g/mL) that were preincubated with 3 H-cholesterol (5Ci/mL). Cells were washed and incubated in equilibration media (2 mg/mL BSA, 1% P/S DMEM) containing oxysterols (10 mol/L, unless otherwise specified). Cells were washed, and cholesterol efflux was determined in the presence or absence of human apoA-I (50 g/mL) in serum-free medium (2 mg/mL BSA, 1% P/S DMEM). After 5 hours, the supernatant was removed and briefly centrifuged to remove nonadherent cells. Macrophages were dissolved in 0.5N NaOH. Radioactivity of aliquots of both supernatants, and dissolved cells was measured by scintillation counting. Cholesterol efflux is expressed as a percentage of 3 H-cholesterol in medium/( 3 H-cholesterol in mediumϩ 3 H-cholesterol in cells)ϫ100%. The radioactivity of apoA-I-free media was subtracted from that of the apoA-I-containing media.
Efflux of Newly Synthesized Cholesterol
Macrophages were incubated in medium (1% FBS, 1% P/S DMEM) containing 3 H-mevalonate (20Ci/mL) and oxysterols (10 mol/L) for 48 hours. Cells were washed, and cholesterol efflux was measured over 24 hours, in the presence or absence of human apoA-I in serum-free medium (2 mg/mL BSA, 1% P/S DMEM). ApoA-I in media aliquots was immunoprecipitated under native conditions with a polyclonal antihuman apoA-1 rabbit antiserum (Calbiochem) and Protein G Sepharose (Amersham Biosciences). The immunoprecipitates were collected after centrifugation and washed 4 times with phosphate-buffered saline and resuspended in a final volume of 0.5 mL for scintillation counting. The radioactivity of the apoA-I-free media was subtracted from that of the apoA-I-containing media. Total cellular protein levels were determined the Markwell Lowry assay. 24 
Intracellular Cholesterol Distribution
Lipids were extracted from the cell lysates 25 and separated by thin layer chromatography on silica gel plates using a nonpolar solvent system (hexane/diethyl ether/acetic acid, 70:30:1) for separation of cholesterol and CE. The bands corresponding to cholesterol and CE were excised and counted for radioactivity. Alternatively, cellular cholesterol and CE were extracted and measured using a fluorometric assay (Cholesterol/Cholesteryl Ester Quantitation Kit, BioVision), according to the manufacturer's instructions.
Western Blot Analysis
Cells were incubated with or without LDL or AcLDL (50 g/mL) for 24 hours, then treated with oxysterols overnight. Cells were washed with PBS, scrapped with lysis buffer (Tris-EDTA-EGTAϩComplete protease inhibitor; Roche) and mechanically homogenized. Total protein samples (25 g per well) were electrophoresed on a precast 8% SDS-polyacrylamide gel (Invitrogen) and transferred to nitrocellulose membranes at 125V for 4 hours. Membranes were incubated overnight with anti-ABCA1 (1:500, Novus Biologicals), anti-ABCG1 (1:2500, Novus Biologicals), anti-␤-Actin (1:500, BioLegend), or anti-Heat Shock Protein 60 (HSP60) (1:500, Sigma). An anti-rabbit secondary antibody conjugated with horseradish peroxidase (Amersham Biosciences) and SuperSignal West Pico Chemiluminescent Substrate (Pierce) were used for detection.
Statistical Analysis
Results are shown as meanϮSEM, and all experiments were run in triplicates. The statistical significance of the differences between groups was determined using Student t test with or without Welsh correction or 1-way ANOVA with Tukey post test using GraphPad InStat v.3.06 statistical analysis software (GraphPad Software Inc).
Results
Epoxycholesterol Promotes Cholesterol Efflux to Lipid-Poor ApoA-I in LDL-Treated But Not in AcLDL-Loaded Macrophages
Bone marrow-derived macrophages (BMDM) were labeled with 3 H-mevalonate in the presence of oxysterols for 48 hours, after which efflux of de novo synthesized cholesterol to apoA-I was measured. In unloaded macrophages (not preincubated with lipoproteins), both 22-HC and epoxycholesterol increased efflux of newly synthesized cholesterol ( Figure 1A ). Epoxycholesterol, which has a higher affinity for LXR than 22-HC, 26 was a stronger inducer of efflux of newly synthesized cholesterol to apoA-I. The observed increase in cholesterol efflux was not attributable to an increase of cholesterol synthesis in response to treatment with oxysterols, because total cholesterol synthesis was decreased in cells treated with oxysterols (data not shown). This is in agreement with the well-documented downregulation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase by oxysterols. [27] [28] [29] The effect of oxysterols on cholesterol efflux in macrophage foam cells has not been well characterized. Here in BMDM foam cells generated by incubating with AcLDL, the net cellular cholesterol level (g/mg cell protein) was 8.7-fold higher compared to unloaded macrophages (488Ϯ18 versus 56Ϯ5). As expected, because of the feedback inhibition of the LDL receptor, the cholesterol content of LDLlabeled macrophages was similar to that of unloaded macro-phages (63Ϯ9 compared to 56Ϯ3). Surprisingly, epoxycholesterol decreased cholesterol efflux to apoA-I in AcLDL-loaded foam cells, whereas 22-HC had a stimulatory effect ( Figure 1B ). This efflux reduction was also observed in macrophages treated with oxLDL and agLDL, 2 other wellknown foam cell inducers, but not in LDL-treated macrophages. Epoxycholesterol not only decreased cholesterol efflux in murine macrophage foam cells, but also in human THP-1 macrophages ( Figure 1C ) and in primary human monocyte-derived macrophages (MDM; Figure 1D ) loaded with AcLDL-derived cholesterol.
In unloaded or LDL-treated macrophages, epoxycholesterol stimulated cholesterol efflux, suggesting that the reduction of efflux in response to epoxycholesterol is specific to the macrophage foam cell ( Figure 1B) . Indeed, when macrophages were loaded with increasing amounts of AcLDLderived cholesterol (Figure 2A ), epoxycholesterol concomitantly reduced cholesterol efflux to apoA-I proportionally to the amount of AcLDL internalized into the cell ( Figure 2B ).
Induction of ABCA1 and ABCG1 Expression by Epoxycholesterol Treatment in AcLDL-Loaded Macrophages Is Not Associated With Enhanced ABCA1-and ABCG1-Mediated Cholesterol Efflux
In AcLDL-loaded BMDM, we observed a dose-dependent decrease of cholesterol efflux to lipid-poor apoA-I in response to epoxycholesterol treatment ( Figure 3A ). Another member of the ATP-binding cassette (ABC) family, ABCG1, has previously been described as a LXR-responsive gene 13, 30 and has an established role in the efflux of cholesterol to high density lipoprotein (HDL) acceptors. 31, 32 Interestingly, increasing doses of epoxycholesterol also correlated with a decrease in cholesterol efflux to HDL in AcLDL-loaded BMDM ( Figure 3B ), indicating that epoxycholesterol does not uniquely affect the ABCA1-mediated pathway. Rather, epoxycholesterol seems to impair cholesterol efflux regardless of the cholesterol acceptor.
The decline of cholesterol efflux occurred in spite of the upregulation of the transporters implicated in these processes. Expression of both ABCA1 ( Figure 3C ) and ABCG1 ( Figure  3D ) was induced by epoxycholesterol, in a dose-dependent fashion, and translocation of the transporters to the plasma membrane was not hindered (data not shown).
Epoxycholesterol Impairs the Mobilization of Cholesterol
Excess cellular cholesterol is stored as CE, which can be mobilized for efflux by CE hydrolase activity. We therefore evaluated the effects of 22-HC and epoxycholesterol on CE stores. In unloaded BMDM, epoxycholesterol dramatically increased the proportion of newly synthesized cholesterol in CE pools ( Figure 4A ). Epoxycholesterol also promoted the accumulation of CE in BMDM incubated with LDL, AcLDL, OxLDL, and AgLDL ( Figure 4B ). In contrast, treatment with 22-HC did not induce a comparable rise in cellular CE. The relative changes in CE levels shown in Figure 4A were indeed representative of net CE accumulation, as confirmed by direct measurement of esterified cholesterol cellular content ( Figure 4C and 4D) . Additionally, epoxycholesterol enhanced cellular CE mass in THP-1 macrophages in both unloaded and AcLDL-loaded cells (Table) . Because the accumulation of CE was specifically attributable to epoxycholesterol treatment, we speculated that this might be implicated in the impairment of cholesterol efflux from epoxycholesterol-treated macrophage foam cells. One of two scenarios (or perhaps a combination of both) could be proposed: Epoxycholesterol promotes the esterification of cholesterol via stimulation of ACAT, or epoxycholesterol decreases CE hydrolysis. In both, availability of free cholesterol for efflux to apoA-I would be decreased. To distinguish between the two, we performed a series of experiments in the presence of an ACAT inhibitor, which was added at key times during the experiments.
First, the ACAT inhibitor was added during treatment with epoxycholesterol, after the cells had been incubated with 3 H-cholesterol-AcLDL for 24 hours. Subsequently, efflux to apoA-I was measured for 5 hours. Whereas the ACAT inhibitor-treated cells displayed increased cholesterol efflux, the addition of epoxycholesterol increased but failed to restore efflux to apoA-I ( Figure 5A ), indicating that the ability of epoxycholesterol to reduce cholesterol efflux in macrophage foam cells is largely independent of cholesterol esterification.
Next, the ACAT inhibitor was administered during labeling of BMDM with LDL-or AcLDL-derived 3 H-cholesterol for 6 hours, as well as during treatment with epoxycholesterol (12 hours) and efflux to apoA-I (5 hours). Under these conditions, cholesterol esterification in the ER for storage in the lipid droplet was inhibited, and essentially Epoxy 450Ϯ24* 177Ϯ11** THP-1 macrophages were incubated for 24 hours in medium containing AcLDL (50 g/mL) or not. Cells were treated with 22(R)-hydroxycholesterol or 24(S),25-epoxycholesterol (10 mol/L) for 12 hours, after which cellular cholesterol mass was measured by fluorometric assay. *PϽ0.05, **PϽ0.01, ***PϽ0.005, or ****PϽ0.0001. all of the lipoprotein-derived 3 H-cholesterol remained unesterified ( Figure 5B ). We observed an increase in both LDL-and AcLDL-derived cholesterol efflux in response to epoxycholesterol treatment ( Figure 5C ), demonstrating that epoxycholesterol does not hinder efflux of unesterified cholesterol, and mediates its effect downstream of cholesterol esterification in the ER.
Finally, to directly assess the degree of CE hydrolysis in response to epoxycholesterol treatment, BMDM were incubated with unlabeled AcLDL in the presence of 3 Holeate for 24 hours, such that AcLDL-derived cholesterol could be esterified to the radio-labeled oleate. Subsequent treatment with epoxycholesterol in the presence of an ACAT inhibitor and apoA-I resulted in equivalent CE cellular content as epoxycholesterol treatment alone (Figure 5D) , therefore allowing us to conclude that epoxycholesterol treatment impairs mobilization of cholesterol from the CE pools. Specifically, epoxycholesterol decreases CE hydrolysis from the lipid droplet, and reduces the availability of free cholesterol for efflux to lipid-poor apoA-I or HDL.
Discussion
Because activated LXRs induce the expression of numerous genes involved in the reverse cholesterol transport pathway, notably ABCA1 and ABCG1, they have become attractive targets for pharmacological treatment of atherosclerosis. 33 Whereas the therapeutic potential of LXR activation has been demonstrated by the targeted disruption of LXR in macrophages in athero-susceptible mice, 34 systemic LXR activation is less favorable because of an associated rise in plasma triglycerides attributed to LXR activation of sterol regulatory element binding protein 1c (SREBP-1c), which induces genes involved in fatty acid and triglyceride synthesis. [35] [36] [37] [38] The naturally occurring oxysterols, 22-HC and epoxycholesterol, are potent LXR ligands. 8 Interestingly, increased epoxycholesterol production in macrophages was recently reported to selectively upregulate cholesterol efflux genes without a simultaneous increase in genes that promote triglyceride synthesis, in contrast to a nonsteroidal synthetic LXR agonist. 14, 39 Given that epoxycholesterol has a higher affinity for LXR than 22-HC 26 and does not promote triglyceride synthesis, 39 we hypothesized that epoxycholesterol should be the most effective oxysterol to induce cholesterol efflux in lipid-loaded macrophages and decrease the foam cell phenotype.
Whereas epoxycholesterol enhanced cholesterol efflux in unloaded or LDL-treated and labeled macrophages in keeping with earlier reports of the effects of oxysterols, 6, [11] [12] [13] it unexpectedly decreased cholesterol efflux in lipid-laden primary murine macrophages generated by incubation with AcLDL, OxLDL, or AgLDL ( Figure 1A and 1B) . Moreover, epoxycholesterol also decreased cholesterol efflux in human THP-1 and monocyte-derived macrophages loaded with AcLDL-derived cholesterol ( Figure 1C and 1D) . In lipidloaded macrophages, epoxycholesterol impaired both ABCA1-mediated cholesterol efflux to lipid-poor apoA-I and ABCG1-mediated cholesterol efflux to HDL (Figure 3A and 3B). The decrease in cholesterol efflux on epoxycholesterol treatment in macrophage foam cells occurred despite the significant upregulation of the ABCA1 and ABCG1 transporters ( Figure 3C and 3D ), in agreement with earlier reports of oxysterol stimulation of ABCA1 11, 13 and ABCG1 32, 40 expression. Interestingly, it has previously been shown that in macrophage foam cells 7-ketocholesterol impairs cholesterol efflux to apoA-I, compared with macrophages loaded with AcLDL alone, thus indicating that this oxysterol also inhibits reverse cholesterol transport in AcLDL-loaded macrophages. 41 CE stored in cytoplasmic lipid droplets must be mobilized by enzymes with CE hydrolase activities before export of cholesterol from the cell via ABCA1-and ABCG1-mediated efflux. We have found that epoxycholesterol reduces cholesterol efflux downstream of the ER-resident enzyme responsible for the esterification of cholesterol ( Figure 5A through 5C). When esterification of cholesterol for storage in the lipid droplets was inhibited via the administration of an ACAT inhibitor, epoxycholesterol enhanced efflux of both LDL-and AcLDL-derived cholesterol. In contrast, epoxycholesterol treatment in the presence of the ACAT inhibitor, after macrophage lipid-loading, leads to a reduction of cholesterol efflux and accumulation of CE in lipid droplets. We thus conclude that epoxycholesterol reduces cholesterol availability for efflux via downregulation of CE hydrolysis.
The exact identity of the enzymes that catalyze CE lipolysis in macrophages remains ambiguous. Whereas the presence of the hormone-sensitive lipase (HSL) in human macrophages is controversial, 42 a neutral CEH gene was cloned from THP-1 and PBMC libraries, 43 the overexpression of which enhanced both ABCA1-and ABCG1-mediated efflux in THP-1 cells. 44 We have investigated whether epoxycholesterol regulates the expression of this human CEH in THP-1 macrophages. Our results indicate that epoxycholesterol does not decrease cholesterol efflux via transcriptional regulation of CEH expression in human macrophages (supplemental Figure IA , available online at http://atvb.ahajournals.org).
Interestingly, we were able to detect HSL mRNA in THP-1 macrophages using the primers designed by Reue et al. 45 However, we did not observe any significant change in HSL mRNA in our treated versus untreated cells (supplemental Figure IB) . Hence, changes in HSL expression at the transcriptional level cannot explain the decrease in CE hydrolysis measured in epoxycholesterol-treated cells. It is, however, unlikely that HSL plays a major role in the CE hydrolysis in these THP-1 macrophages given that its mRNA levels were strikingly lower, by as much as 20 000-fold, compared to CEH mRNA. Conversely, as one early study has shown, for certain hydrolases there is little correlation between mRNA levels and lipolytic activity. 46 It remains to be determined how epoxycholesterol decreases CE hydrolysis in lipid-loaded macrophages. We do know that this occurs independently of LXR activation, because the simultaneous treatment of lipid-loaded THP-1 cells with epoxycholesterol and an LXR antagonist does not increase cholesterol efflux, and the addition of an LXR synthetic agonist in conjunction with epoxycholesterol fails to rescue the efflux defect (supplemental Figure II) . Although epoxycholesterol does not reduce CE lipolysis in lipid-loaded macrophages via transcriptional downregulation of CEH or HSL, the possibility of altered posttranslational regulation of these enzymes remains to be investigated, as well as the contribution of other candidate enzymes for CE hydrolysis in these macrophages. It is worth to note that other lipid droplet associated proteins, such as perilipin and adipocyte differentiation-related protein (ADRP), were reported to influence lipid hydrolysis by regulating the accessibility of the hydrolytic enzymes to lipids within the droplet core. The examination of the effects of epoxycholesterol on these proteins is underway.
Potential LXR agonists for therapeutic intervention in atherosclerosis need to be selected with extreme caution. As shown here, an increase in the expression of ABCA1 and ABCG1 transporters does not necessarily translate into enhancement of cholesterol efflux from the macrophage. We have observed that once the macrophage becomes cholesterol-loaded, its response to oxysterols differs than that observed in unloaded and LDL-loaded macrophages. Our results indicate that 22-HC is better capable of promoting cholesterol efflux in lipid-laden macrophages, whereas epoxycholesterol appears to impair this process. In conclusion, epoxycholesterol elicits cholesterol efflux from noncholesterol loaded cells but aggravates the phenotype of the macrophage foam cell. Hence, epoxycholesterol may have quite different effects on the prophylaxis versus regression of atherosclerosis.
